Page 21 - My FlipBook

Index

alleles, 22–23, 89 Genetic Information
Aristotle, 19 Nondiscrimination Act, 91
autoimmune disorders, 8, 14–17 eugenics, 26–28, 87, 120
celiac disease, 5 exons, 10, 69, 95
common variable immune deficiency
(CVID), 8–9, 14 fragile X, 65, 71, 124
Crohn’s disease, 6
severe combined immunodeficiency gametes. See sex cells
(SCID), 44, 104 gene editing, 6–7, 26, 108, 110, 113,
type 1 diabetes, 5–6 116–117, 122, 125
CRISPR-Cas9, 110–115
base pairs, 50–53, 62, 66–67, 69–71, 95 CRISPR-Cas10, 117
genes, 6, 9–10, 18, 22–23, 25, 29–30,
cancer, 5, 15, 35, 37, 71, 83–84, 95, 101, 50–52, 62–63, 66, 108–109, 123
108, 110, 124 beta-globin gene (HBB), 104, 107
chromosomes, 10, 13, 20–21, 29–31, BRCA1, 37
52, 58–59, 65–66, 70, 80 BRCA2, 37, 83–84
codons, 53, 71 BRCA3, 83–84, 95
cystic fibrosis (CF), 43, 57–59 BRCA4, 95
CCR5, 114–115
direct-to-consumer tests, 6, 76, 79, CFTR, 57–59
83–87, 89–91, 95, 98–99, 101 CTLA4, 15–16
African Ancestry, 85–86 FMR-1, 71
Ancestry, 85–88, 90, 92, 95 HLA-B51, 17
Color, 101 KAT6A, 74–76
FamilyTreeDNA, 81–82, 91, 93 PAH, 39–40, 47, 53
Genos, 95–99 PMM2, 97
23andMe, 83, 86–88, 90, 92, 94–95, variants, 9, 13, 22–25, 68–69, 71–74,
97–100 80, 83–86, 89–90, 94–99, 101
DNA, 13, 26, 50–51, 57–59, 66–68, gene therapy, 6–7, 103–104, 106–110,
71, 79, 89, 103, 107–110, 112–113, 122
115–117, 123–124 genetic evidence, 18, 55, 92–93
mitochondrial, 80–81 genetic sequencing, 6, 40, 51, 57,
noncoding, 10, 60, 63, 69–70 59–60, 62, 109, 124
polymerase, 53–54 next-generation sequencing (NGS),
replication, 53–56 6, 67, 69–72, 74, 77, 101, 109
structure of, 6, 30–37, 52, 113 Sanger sequencing, 6, 53, 55–56,
testing, 79, 83–85, 87–88, 90–97, 63, 67
95, 99–101. (see also direct-to- whole exome sequencing, 69–70,
consumer tests) 74–76, 95, 101
dominant, 23–24, 74 whole genome sequencing, 69–70,
72, 76, 95, 101, 103, 114
epigenetics, 19, 30 genetic testing, 6, 11, 13, 16–17, 21,
ethics, 6, 76, 84, 86, 114–116, 122 50–51, 61, 65, 67, 75–76, 87, 103,
ethical, legal, and social issues 118–119, 121–124.
(ELSI), 60–61 See also direct-to-consumer tests)

142